Under Right to Try laws, terminally ill patients may be granted the right to access and use investigational products (i.e., medications or treatments) that are not yet publicly available because they are being investigated by the US Food and Drug Administration (FDA). The FDA must be actively investigating the product, and it must have already passed Phase I of the approval process. This interactive map explores state laws that govern the criteria a patient must meet to be eligible to access the products. It also addresses insurance coverage for these investigational products, specifically whether insurers are required to pay for coverage, and whether patients may have to forfeit coverage or care if they choose to use Right to Try laws to access these treatments.
This dataset identifies and displays key features of Right to Try laws across all 50 states and the District of Columbia, and over time, from January 1, 2014 to October 1, 2016.